These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23603101)

  • 61. Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.
    Oonk S; Spitali P; Hiller M; Switzar L; Dalebout H; Calissano M; Lochmüller H; Aartsma-Rus A; 't Hoen PA; van der Burgt YE
    Proteomics Clin Appl; 2016 Mar; 10(3):290-9. PubMed ID: 26680509
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of the TRPV2 Inhibitor on Advanced Heart Failure in Patients with Muscular Dystrophy: Exploratory Study of Biomarkers Related to the Efficacy of Tranilast.
    Takahashi C; Oishi M; Iwata Y; Maekawa K; Matsumura T
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768491
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated Prostaglandin E
    Gartner S; Roca-Ferrer J; Fernandez-Alvarez P; Lima I; Rovira-Amigo S; García-Arumi E; Tizzano EF; Picado C
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610815
    [No Abstract]   [Full Text] [Related]  

  • 64. Developmental lag of visuospatial attention in Duchenne muscular dystrophy.
    Piccini G; Gazzellini S; D'Amico A; Pane M; Castelli E; Vicari S; Alfieri P
    Res Dev Disabil; 2015 Jan; 36C():55-61. PubMed ID: 25462465
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Urinary PGDM, a prostaglandin D
    Inagaki S; Maeda S; Narita M; Nakamura T; Shimosawa T; Murata T; Ohya Y
    J Allergy Clin Immunol; 2018 Nov; 142(5):1634-1636.e10. PubMed ID: 29981807
    [No Abstract]   [Full Text] [Related]  

  • 66. The free cytoplasmic Ca2+ levels in Duchenne muscular dystrophy lymphocytes.
    Klip A; Elder B; Ruiz-Funes HP; Buchwald M; Grinstein S
    Muscle Nerve; 1985 May; 8(4):317-20. PubMed ID: 16758598
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Can urinary titin be used for predicting Duchenne muscular dystrophy?
    Matsuo M; Awano H; Nishio H
    Clin Chim Acta; 2019 Mar; 490():162. PubMed ID: 30395868
    [No Abstract]   [Full Text] [Related]  

  • 68. Synthesis of a Human Urinary Metabolite of Prostaglandin D
    Kimbrough JR; Austin Z; Milne GL; Sulikowski GA
    Org Lett; 2019 Dec; 21(24):10048-10051. PubMed ID: 31799855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Can urinary titin be used for predicting Duchenne muscular dystrophy?
    Bai SM; Guo XX
    Clin Chim Acta; 2019 Mar; 490():161. PubMed ID: 30391395
    [No Abstract]   [Full Text] [Related]  

  • 70. Urinary PGE
    Hamrin J; Perez-Manzo M; Idborg H; Jakobsson PJ; Björk L; Eriksson M; Nilsson A; Herlenius E
    Acta Paediatr; 2019 Oct; 108(10):1879-1886. PubMed ID: 30933389
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An experienced leader Lili K. Horton, DMD, MS.
    Horton LK; Wada C
    Hawaii Dent Assoc J; 2014; ():22-3. PubMed ID: 25004678
    [No Abstract]   [Full Text] [Related]  

  • 72. Special tests Special tests Evans DMD Faber 278pp £3.95 0-571-15205-8.
    Nurs Stand; 1989 Jun; 3(39):42. PubMed ID: 27224802
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First DMD Drug Gains Approval.
    Voelker R
    JAMA; 2016 Nov; 316(17):1756. PubMed ID: 27802526
    [No Abstract]   [Full Text] [Related]  

  • 74. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation.
    Awad JA; Morrow JD; Roberts LJ
    J Allergy Clin Immunol; 1994 May; 93(5):817-24. PubMed ID: 8182221
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.
    Komaki H; Maegaki Y; Matsumura T; Shiraishi K; Awano H; Nakamura A; Kinoshita S; Ogata K; Ishigaki K; Saitoh S; Funato M; Kuru S; Nakayama T; Iwata Y; Yajima H; Takeda S
    Ann Clin Transl Neurol; 2020 Feb; 7(2):181-190. PubMed ID: 31957953
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase I study of TAS-205 in patients with Duchenne muscular dystrophy.
    Takeshita E; Komaki H; Shimizu-Motohashi Y; Ishiyama A; Sasaki M; Takeda S
    Ann Clin Transl Neurol; 2018 Nov; 5(11):1338-1349. PubMed ID: 30480028
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.
    McDonald C; Camino E; Escandon R; Finkel RS; Fischer R; Flanigan K; Furlong P; Juhasz R; Martin AS; Villa C; Sweeney HL
    J Neuromuscul Dis; 2024; 11(2):499-523. PubMed ID: 38363616
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hematopoietic Prostaglandin D Synthase Is Increased in Mast Cells and Pericytes in Autopsy Myocardial Specimens from Patients with Duchenne Muscular Dystrophy.
    Hamamura K; Yoshida Y; Oyama K; Li J; Kawano S; Inoue K; Toyooka K; Yamadera M; Matsunaga N; Matsumura T; Aritake K
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339125
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions.
    Fortunato F; Ferlini A
    J Neuromuscul Dis; 2023; 10(6):987-1002. PubMed ID: 37545256
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.